<!DOCTYPE html>
<html lang="en"><head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1" name="viewport"/>
<link href="https://cdn-icons-png.flaticon.com/512/4021/4021693.png" rel="icon"/>
<link href="../style.css" rel="stylesheet"/>
<link href="https://fonts.googleapis.com" rel="preconnect"/>
<link crossorigin="" href="https://fonts.gstatic.com" rel="preconnect"/>
<link href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600&amp;family=Space+Mono:wght@400;700&amp;display=swap" rel="stylesheet"/>
<title>Trimethoprim/Sulfamethoxazole</title>
</head><body><main class="container"><header class="site-header">
<h1 class="logo"><a href="../index.html">r/anhedonia</a></h1>
<p class="subtitle">Personal Wiki</p>
</header><nav style="margin-bottom: 20px;"><a href="../actions.html">← Back to Personal Wiki</a></nav><section class="card"><h2>Trimethoprim/Sulfamethoxazole</h2><ul>
<li><img src="https://upload.wikimedia.org/wikipedia/commons/thumb/e/e8/Trimethoprim_and_sulfamethoxazole.svg/250px-Trimethoprim_and_sulfamethoxazole.svg.png"/></li>
<li>Pharmacological Actions and Temporal Influences</li>
<li>TMP-SMX is an antimicrobial combination primarily used to treat and prevent bacterial infections by targeting folate synthesis, a critical pathway for bacterial DNA and protein synthesis. Sulfamethoxazole, a sulfonamide, acts as a competitive inhibitor of dihydropteroate synthase, preventing the conversion of p-aminobenzoic acid (PABA) to dihydropteroate, an early step in folate synthesis. Trimethoprim complements this by inhibiting dihydrofolate reductase, blocking the reduction of dihydrofolate to tetrahydrofolate, the active form needed for purine synthesis. This dual inhibition creates a synergistic effect, often rendering the combination bactericidal, particularly in environments like urine, where concentrations can be high.</li>
<li>The pharmacodynamic profile suggests a time-dependent killing mechanism, akin to beta-lactams and macrolides, where efficacy is maximized by maintaining drug concentrations above the minimum inhibitory concentration (MIC) for a significant portion of the dosing interval. This is supported by studies indicating that the duration of exposure, rather than peak concentration, correlates with bacterial kill rates. For instance, research on E. coli showed significant CFU reductions at concentrations above MIC for extended periods, with pharmacodynamic thresholds like fAUC/MIC ratios (e.g., 40.7 for stasis, 59.5 for 1-log reduction) highlighting the importance of time above MIC.</li>
<li>Temporal influences include:</li>
<ul>
<li>Onset of Action: Peak blood levels occur 1-4 hours post-oral administration, with steady-state concentrations achieved after approximately 3 days of repeat dosing.</li>
<li>Duration of Effect: Given the half-lives (6-12 hours for sulfamethoxazole, 8-10 hours for trimethoprim), dosing every 12 hours ensures adequate coverage, aligning with time-dependent killing requirements.</li>
</ul>
<li>Half-Life and Bioavailability</li>
<li>The half-life of sulfamethoxazole ranges from 6 to 12 hours in healthy individuals, extending to 20-50 hours in renal failure due to reduced clearance. Trimethoprim has a half-life of 8-10 hours, which may prolong in renal dysfunction. These values are critical for dosing intervals to maintain therapeutic levels.</li>
<li>Bioavailability is high for both components via the oral route:</li>
<ul>
<li>Sulfamethoxazole: Approximately 85-90%, with rapid absorption and distribution into various fluids like sputum, vaginal fluid, and breast milk.</li>
<li>Trimethoprim: Close to 100%, as evidenced by studies in AIDS patients showing oral bioavailability of 102.7% ± 19.8%, suggesting near-complete absorption, with values over 100% likely due to measurement variability.</li>
</ul>
<li>Other routes, such as intravenous, are used in severe cases, but oral administration is standard due to high bioavailability, ensuring systemic efficacy.</li>
<li>Dosage Regimens</li>
<li>Dosage varies by indication, patient factors, and renal function, as detailed below:</li>
<ul>
<li><table>
<tr>
<th>Indication</th>
<th>Dosage (Adult, ≥40kg)</th>
<th>Duration</th>
</tr>
<tr>
<td>Bacterial Infections (e.g., UTI)</td>
<td>800 mg SMX + 160 mg TMP every 12 hours</td>
<td>10-14 days</td>
</tr>
<tr>
<td>Pneumocystis jirovecii Pneumonia (Treatment)</td>
<td>75-100 mg/kg SMX + 15-20 mg/kg TMP daily, divided</td>
<td>14-21 days</td>
</tr>
<tr>
<td>Pneumocystis jirovecii Pneumonia (Prophylaxis)</td>
<td>800 mg SMX + 160 mg TMP daily</td>
<td>Continuous</td>
</tr>
<tr>
<td>Traveler's Diarrhea</td>
<td>800 mg SMX + 160 mg TMP every 12 hours</td>
<td>5 days</td>
</tr>
<tr>
<td>Chronic Bronchitis (Acute Exacerbation)</td>
<td>800 mg SMX + 160 mg TMP every 12 hours</td>
<td>10-14 days</td>
</tr>
<tr>
<td>Shigellosis</td>
<td>800 mg SMX + 160 mg TMP every 12 hours</td>
<td>5 days</td>
</tr>
</table></li>
</ul>
<li>Safe Range and Adjustments:</li>
<ul>
<li>Standard doses are generally safe for adults without comorbidities. For renal impairment, adjust as follows:</li>
<ul>
<li>CrCl &gt;30 mL/min: No change.</li>
<li>CrCl 15-30 mL/min: Reduce dose by 50%.</li>
<li>CrCl &lt;15 mL/min: Avoid use.</li>
</ul>
<li>Not recommended for infants &lt;2 months due to toxicity risks like hyperbilirubinemia.</li>
</ul>
<li>Minimum Effective Dose: Depends on infection and bacterial susceptibility; prophylaxis uses lower doses (e.g., 800 mg SMX + 160 mg TMP daily or thrice weekly).</li>
<li>Maximum Safe Dose: Up to 100 mg/kg SMX + 20 mg/kg TMP per day for severe infections, but increased monitoring is required due to higher adverse effect risks, especially in elderly or immunocompromised patients.</li>
<li>Toxicity and Safety Thresholds</li>
<li>Toxicity data from animal studies provide insight into lethal doses:</li>
<ul>
<li>Trimethoprim LD50: &gt;5300 mg/kg oral in rats.</li>
<li>Sulfamethoxazole LD50: 2300 mg/kg in mice, 6200 mg/kg in rats.</li>
</ul>
<li>In humans, LD50 is not ethically determined, but therapeutic doses are significantly lower, with toxicity manifesting at standard doses in susceptible individuals. Common adverse effects include nausea, diarrhea, and skin rashes, while severe reactions include Stevens-Johnson syndrome, toxic epidermal necrolysis, and hematological toxicities like thrombocytopenia or leukopenia, particularly at higher doses or in patients with renal impairment.</li>
<li>When It Becomes Too Dangerous:</li>
<ul>
<li>Toxicity becomes significant with signs like severe skin reactions, significant blood count drops, or hyperkalemia, necessitating immediate dose adjustment or discontinuation. Elderly patients, those with kidney issues, or those on interacting medications (e.g., diuretics, digoxin) are at higher risk, requiring careful monitoring.</li>
</ul>
</ul></section><footer class="site-footer">
<p><a href="../index.html">← Back to Home</a></p>
</footer></main><script src="../js/router.js"></script></body></html>